PremiumCompany AnnouncementsHUTCHMED Secures NMPA Approval for TAZVERIK® in China HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating HUTCHMED Announces Board Changes Following Director Retirements PremiumCompany AnnouncementsHUTCHMED Achieves Profitability with Strong Oncology Growth and Strategic Developments Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab HUTCHMED and Innovent’s Combination Therapy Shows Promise in Advanced Renal Cell Carcinoma PremiumCompany AnnouncementsHUTCHMED Appoints Alvin Wong as Independent Non-executive Director HUTCHMED Announces Major Equity Disposal in SHPL HUTCHMED Updates on Disposal of Shanghai Hutchison Pharmaceuticals Stake